Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

NCT01658176 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: PF-04691502
DRUG: Exemestane
DRUG: Exemestane

Sponsor

Pfizer